Compare ADPT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | TNGX |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.1B |
| IPO Year | 2019 | 2020 |
| Metric | ADPT | TNGX |
|---|---|---|
| Price | $27.73 | $21.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $33.86 | ★ $47.00 |
| AVG Volume (30 Days) | 2.1M | ★ 3.6M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $276,976,000.00 | $62,384,000.00 |
| Revenue This Year | $10.85 | N/A |
| Revenue Next Year | $21.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 54.77 | 48.29 |
| 52 Week Low | $12.00 | $8.30 |
| 52 Week High | $32.21 | $34.39 |
| Indicator | ADPT | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 49.06 | 44.62 |
| Support Level | $24.02 | $20.49 |
| Resistance Level | $29.92 | $22.01 |
| Average True Range (ATR) | 1.71 | 1.92 |
| MACD | -0.09 | -0.15 |
| Stochastic Oscillator | 31.91 | 18.52 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.